Sarcosine Therapy for Obsessive Compulsive Disorder
Authors:
- Hwa-Sheng TangHTHwa-Sheng Tang
- Hsien-Yuan LaneHLHsien-Yuan Lane
- Chen-An TsaiCTChen-An Tsai
- Guochuan E. TsaiGTGuochuan E. Tsai
- 1 June 2011
- journal article
- research article
- Published by Wolters Kluwer Health in Journal of Clinical Psychopharmacology
- Vol. 31 (3) , 369-374
Abstract
Several lines of evidence implicate glutamatergic neurotransmission in the pathophysiology of obsessive compulsive disorder (OCD). Sarcosine is an endogenous antagonist of glycine transporter-1. By blocking glycine uptake, sarcosine may increase the availability of synaptic glycine and enhance N-methyl-d-aspartate (NMDA) subtype glutamatergic neurotransmission. In this 10-week open-label trial, we examined the potential benefit of sarcosine treatment in OCD patients. Twenty-six outpatients with OCD and baseline Yale-Brown Obsessive Compulsive Scale (YBOCS) scores higher than 16 were enrolled. Drug-naive subjects (group 1, n = 8) and those who had discontinued serotonin reuptake inhibitors for at least 8 weeks at study entry (group 2, n = 6) received sarcosine monotherapy. The other subjects (group 3, n = 12) received sarcosine as adjunctive treatment. A flexible dosage schedule of sarcosine 500 to 2000 mg/d was applied. The primary outcome measures were Y-BOCS and Hamilton Anxiety Inventory, rated at weeks 0, 2, 4, 6, 8, and 10. Results were analyzed by repeated-measures analysis of variance. Data of 25 subjects were eligible for analysis. The mean ± SD Y-BOCS scores decreased from 27.6 ± 5.8 to 22.7 ± 8.7, indicating a mean decrease of 19.8% ± 21.7% (P = 0.0035). Eight (32%) subjects were regarded as responders with greater than 35% reduction of Y-BOCS scores. Five of the responders achieved the good response early by week 4. Although not statistically significant, drug-naive (group 1) subjects had more profound and sustained improvement and more responders than the subjects who had received treatment before (groups 2 and 3). Sarcosine was tolerated well; only one subject withdrew owing to transient headache. Sarcosine treatment can achieve a fast therapeutic effect in some OCD patients, particularly those who are treatment naive. The study supports the glycine transporter-1 as a novel target for developing new OCD treatment. Large-series placebo-controlled, double-blind studies are recommended.Keywords
This publication has 37 references indexed in Scilit:
- Adjunctive glycine in the treatment of obsessive-compulsive disorder in adultsJournal of Psychiatric Research, 2009
- Glutamatergic Synaptic Dysfunction and Obsessive-Compulsive DisorderCurrent Chemical Genomics, 2008
- Lamotrigine as an augmentation agent in treatment-resistant obsessive-compulsive disorder: a case reportJournal of Psychopharmacology, 2008
- Riluzole Augmentation in Treatment-Refractory Obsessive-Compulsive DisorderJournal of Clinical Psychopharmacology, 2008
- An Open-Label Trial of Riluzole, a Glutamate Antagonist, in Children with Treatment-Resistant Obsessive-Compulsive DisorderJournal of Child and Adolescent Psychopharmacology, 2007
- Topiramate augmentation in treatment-resistant obsessive–compulsive disorder: a retrospective, open-label case seriesDepression and Anxiety, 2006
- Riluzole Augmentation in Treatment-Resistant Obsessive–Compulsive Disorder: An Open-Label TrialBiological Psychiatry, 2005
- Reduced Anterior Cingulate Glutamatergic Concentrations in Childhood OCD and Major Depression Versus Healthy ControlsJournal of the American Academy of Child & Adolescent Psychiatry, 2004
- Obsessive–Compulsive DisorderNew England Journal of Medicine, 2004
- On the role of cortical glutamate inobsessive‐compulsive disorder and attention‐deficit hyperactivity disorder, two phenomenologically antithetical conditionsActa Psychiatrica Scandinavica, 2000